{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:04:23Z","timestamp":1780697063465,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijrobp.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T11:57:24Z","timestamp":1688039844000},"page":"1096-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG\/TROG\/NHMRC CTC\/EORTC\/CCTG)"],"prefix":"10.1016","volume":"117","author":[{"given":"Jelena","family":"Lukovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahida","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Akra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Lim Joon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty L.","family":"Wiltshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolie G.","family":"Ringash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Haustermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.06.011_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0002","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0003","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0004","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0006","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2020.11.004","article-title":"Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial","volume":"32","author":"de Steur","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0007","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: The ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0009","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.2014.58.3930","article-title":"Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses","volume":"33","author":"Park","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0010","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12885-015-1529-x","article-title":"TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG)","volume":"15","author":"Leong","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0360-3016(01)02646-3","article-title":"Gastric surgical adjuvant radiotherapy consensus report: Rationale and treatment implementation","volume":"52","author":"Smalley","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0012","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2009.11.042","article-title":"Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: A multicenter study of the Trans-Tasman Radiation Oncology Group","volume":"79","author":"Leong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0013","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2006.06.4840","article-title":"Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response","volume":"24","author":"Ajani","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0014","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1259\/bjr\/43441736","article-title":"Intensity-modulated radiation therapy in the treatment of gastric cancer: Early clinical outcome and dosimetric comparison with conventional techniques","volume":"79","author":"Milano","year":"2006","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0015","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2005.03.013","article-title":"IMRT for adjuvant radiation in gastric cancer: A preferred plan?","volume":"63","author":"Ringash","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0016","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2007.07.001","article-title":"Quality assurance of dosimetry and the impact on sample size in randomized clinical trials","volume":"86","author":"Pettersen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0017","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2011.05.073","article-title":"Quality assurance for prospective EORTC radiation oncology trials: The challenges of advanced technology in a multicenter international setting","volume":"100","author":"Weber","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","article-title":"QA makes a clinical trial stronger: Evidence-based medicine in radiation therapy","volume":"105","author":"Weber","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0019","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: A meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0020","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0021","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 \u2013 A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0022","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone","volume":"19","author":"Duhmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0023","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/S0167-8140(22)02321-0","article-title":"Quality assurance of preoperative radiotherapy in the CRITICS-II gastric cancer trial","author":"Slagter","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0024","series-title":"Quality Assurance in Radiotherapy","year":"1998"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.radonc.2014.03.023","article-title":"Radiation therapy quality assurance in clinical trials \u2013 Global harmonization group","volume":"111","author":"Melidis","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2020.05.038","article-title":"Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines","volume":"150","author":"Mir","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0027","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijrobp.2011.12.080","article-title":"Redesigning radiotherapy quality assurance: Opportunities to develop an efficient, evidence-based system to support clinical trials \u2013 Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance","volume":"83","author":"Bekelman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0028","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1002\/cam4.1756","article-title":"Patient choice for high-volume center radiation impacts head and neck cancer outcome","volume":"7","author":"Naghavi","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0029","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0959-8049(03)00487-8","article-title":"Impact of the treating institution on the survival of patients with head and neck cancer treated with concomitant alternating chemotherapy and radiation","volume":"39","author":"Benasso","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2012.02.010","article-title":"Heterogeneity in head and neck IMRT target design and clinical practice","volume":"103","author":"Hong","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0031","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archsurg.2010.232","article-title":"Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea","volume":"145","author":"Jan","year":"2010","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0032","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.sla.0000245469.35088.42","article-title":"Impact of hospital volume on recurrence and survival after surgery for gastric cancer","volume":"245","author":"Enzinger","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0033","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1245\/s10434-021-09655-y","article-title":"Redefining high-volume gastric cancer centers: The impact of operative volume on surgical outcomes","volume":"28","author":"Ju","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2023.06.011_bib0034","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.radonc.2012.04.015","article-title":"EORTC Radiation Oncology Group quality assurance platform: Establishment of a digital central review facility","volume":"103","author":"Fairchild","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623006016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623006016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:08:28Z","timestamp":1759745308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623006016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0360301623006016"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Feasibility of Quality Assurance in the TOPGEAR International Phase 3 Clinical Trial of Neoadjuvant Chemoradiation Therapy for Gastric Cancer (an Intergroup Trial of the AGITG\/TROG\/NHMRC CTC\/EORTC\/CCTG)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}